You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Antimicrobial Resistance (AMR)

Test Information
Masthead
Masthead-mobile

Diagnostic Solutions for Pharma

Contact

The GeneXpert® system from Cepheid enables standardized, central-lab quality molecular diagnostic testing at the point-of-care to:

  • Accelerate clinical trial enrollment by bringing the test to trial sites
  • Reach diverse populations through a point-of-need test-and-treat program
  • Improve accessibility of companion and complementary diagnostics

Cepheid has Partnered with Pharma to Support Clinical Trials Worldwide for over a decade(1)

The Preferred Simple, and Real-time Diagnostic Solution for Clinical Trials

The GeneXpert system is a point-of-care molecular diagnostic solution, automating the complex, manual steps of polymerase chain reaction (PCR), while combining fast turnaround times with simple workflows for real-time PCR results.

 

Improve Patient Outcomes with a Test-and-Treat Program

Xpert® tests provide medically actionable information for patients to receive same-day treatment

GeneXpert Xpress systems run CLIA waived tests in the U.S.

Comprehensive PCR Menu

The GeneXpert® family of systems can run any of Cepheid's 34 CE-IVD and 22 US-IVD tests to provide accurate, high-quality, real-time PCR results.

GeneXpert Family of Systems

Available in two, four, 16, 48, or 80-module configurations, the GeneXpert platform is both standardized and scalable across the clinical trial continuum — from central labs to remote trial sites to mobile testing.

Interested in Partnering with Cepheid?

Request Info

US-IVD. In Vitro Diagnostic Medical Device.
*data retrieved from internal Cepheid reports.

1. PR Newswire. Cepheid Collaborates With Pharmaceutical Leader on Chronic Myelogenous Leukemia. Accessed Oct. 12, 2022. http://cepheid.mediaroom.com/2010-10-07-Cepheid-Collaborates-With-Pharmaceutical-Leader-on-Chronic-Myelogenous-Leukemia

 

 

Back to Top